Reports Q1 revenue $10.26M, consensus $4.68M. “CytomX has continued to gain tremendous momentum in 2026 and we remain highly focused on executing against the multiple layers of potential value creation we see for Varseta-M. Our top priority is to advance this highly differentiated, first in class EpCAM ADC into a registrational study in late-line CRC while also investing to unlock the broader potential of Varseta-M in earlier line CRC and other cancers,” said Dr. Sean McCarthy, chairman and CEO of CytomX Therapeutics (CTMX).”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics participates in a conference call with JPMorgan
- CytomX Therapeutics Signals Progress in Varseta-M Trial
- 3 Best Stocks to Buy Today, 3/23/2026, According to Top Analysts
- CytomX Therapeutics price target raised to $12 from $10 at Piper Sandler
- CytomX Therapeutics Raises $234 Million in Equity Offering